Strengthening the drug supervision ability has become a key task for the development of the pharmaceutical industry in various regions

Drug safety is a people's livelihood project and a people-friendly project. In recent years, in order to further ensure the quality and safety of drugs, various places have issued documents one after another, clearly expressing the need to strengthen the construction of drug supervision capacity and promote the high-quality development of the pharmaceutical industry. It is reported that since the beginning of this year, many places have successively issued documents stating that they will strengthen the construction of drug supervision capacity.

For example, recently, the Shandong provincial government issued the "Several Measures on Comprehensively Strengthening the Construction of Drug Regulatory Capability" (hereinafter referred to as "Several Measures"), proposing to strive to establish and improve a scientific, efficient and professional drug regulatory system within three years, and further Improve the scientific, legal, modern, and intelligent level of drug supervision work, make every effort to create a drug safety demonstration province, and better protect the public's drug safety.

It is understood that the "Several Measures" mainly focus on six aspects of capacity building, namely, the ability to serve enterprises, the ability to review and approve, the ability to inspect and law enforcement, the ability to technical support, the ability to prevent and control risks, and the Improve policy support capabilities.

Prior to this, the General Office of the People's Government of Shanxi Province also issued the "Notice on Comprehensively Strengthening the Construction of Drug Supervision and Administration", proposing 23 specific measures and requirements from the three aspects of overall requirements, key tasks and safeguard measures, focusing on strengthening the foundation and making up for shortcomings. We will further improve the regulatory system, improve the regulatory mechanism, promote regulatory innovation, and comprehensively strengthen the building of drug regulatory capabilities.

Overall, the "Notice" clarifies 18 key tasks in six areas. Among them, it is worth mentioning that the "Notice" clearly states that it is necessary to build a drug information traceability supervision platform in the province, strengthen the application of "two products and one machine" supervision big data, improve the application service level of "Internet + drug supervision", and comprehensively improve Smart supervision capabilities.

In addition to the above provinces, some time ago, Gansu Province, Jiangxi Province and other places have also issued relevant documents that can suit their own development and can strengthen their drug regulatory capabilities. In this regard, the analysis believes that judging from the current state is vigorously promoting the high-quality development of the pharmaceutical industry, there will be many provinces and cities in the future in order to better ensure drug safety, standardization and healthy development, and will also issue relevant policies and measures to strengthen drug supervision. Skill building. In this context, the pharmaceutical industry will face stricter standards, stricter supervision, stricter penalties, and more serious accountability. But at the same time, the construction of domestic drug regulatory capacity will also reach a new level, and will help the pharmaceutical industry to accelerate its development towards high quality.